RNA replicons provide the genetic instructions to the body’s own cells to produce ample amounts of protein and unleash an immune response. Replicons carry the RNA code for a self-replication engine as well as multiple antigens that signal for immune response. RNA replicons can trigger antigen expression within host cells, increase T-cell response (including when the host is already infected), and lower dose requirements compared to traditional RNA-based vaccine and therapeutic approaches.
February 12, 2018
Arcturus Therapeutics Appoints Dr. Christine Esau as Vice President of Research and Development
February 2, 2018
Arcturus Therapeutics Appoints Mark Herbert as Interim President
January 4, 2018
CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics